Free Trial

Myomo Q1 2023 Earnings Report

Myomo logo
$6.12 +0.03 (+0.49%)
(As of 12/20/2024 05:31 PM ET)

Myomo EPS Results

Actual EPS
-$0.11
Consensus EPS
-$0.15
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

Myomo Revenue Results

Actual Revenue
$3.45 million
Expected Revenue
$3.33 million
Beat/Miss
Beat by +$120.00 thousand
YoY Revenue Growth
N/A

Myomo Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

We recommended Palantir in 2021, now we’re recommending this... (Ad)

My research indicates there is only one investment that can meet AI's unprecedented demand for energy.

Click to get the name and ticker symbol

Myomo Earnings Headlines

Myomo 3M share Spot Secondary priced at $5.00
The #1 Coin for November 2024
Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide…
Myomo dips on $15M equity offering
See More Myomo Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Myomo? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Myomo and other key companies, straight to your email.

About Myomo

Myomo (NYSEAMERICAN:MYO), a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. It also provides the MyoPro 2, including control technology, configuration software and user interface, and pop-out battery for extended use of the brace; and MyoPro2+ that comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products through various sales channels, including orthotics and prosthetics providers, the Veterans Administration, and its distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.

View Myomo Profile

More Earnings Resources from MarketBeat

Upcoming Earnings